PURPOSE: Whirlin is the causative gene for Usher syndrome type IID (USH2D), a condition manifested as both retinitis pigmentosa and congenital deafness. Mutations in this gene cause disruption of the USH2 protein complex composed of USH2A and VLGR1 at the periciliary membrane complex (PMC) in photoreceptors. In this study, the adeno-associated virus (AAV)-mediated whirlin replacement was evaluated as a treatment option. METHODS: Murine whirlin cDNA driven by the human rhodopsin kinase promoter (hRK) was packaged as an AAV2/5 vector and delivered into the whirlin knockout retina through subretinal injection. The efficiency, efficacy, and safety of this treatment were examined using immunofluorescent staining, confocal imaging, immunoelectron microscopy, Western blot analysis, histologic analysis, and electroretinogram. RESULTS: The AAV-mediated whirlin expression started at two weeks, reached its maximum level at 10 weeks, and lasted up to six months post injection. The transgenic whirlin product had a molecular size and an expression level comparable to the wild-type. It was distributed at the PMC in both rod and cone photoreceptors from the central to peripheral retina. Importantly, the transgenic whirlin restored the cellular localization and expression level of both USH2A and VLGR1 and did not cause defects in the retinal histology and function in the whirlin knockout mouse. CONCLUSIONS: Whirlin transgene recruits USH2A and VLGR1 to the PMC and is sufficient for the formation of the USH2 protein complex in photoreceptors. The combined hRK and AAV gene delivery system could be an effective gene therapy approach to treat retinal degeneration in USH2D patients. Copyright 2011 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE:Whirlin is the causative gene for Usher syndrome type IID (USH2D), a condition manifested as both retinitis pigmentosa and congenital deafness. Mutations in this gene cause disruption of the USH2 protein complex composed of USH2A and VLGR1 at the periciliary membrane complex (PMC) in photoreceptors. In this study, the adeno-associated virus (AAV)-mediated whirlin replacement was evaluated as a treatment option. METHODS:Murinewhirlin cDNA driven by the human rhodopsin kinase promoter (hRK) was packaged as an AAV2/5 vector and delivered into the whirlin knockout retina through subretinal injection. The efficiency, efficacy, and safety of this treatment were examined using immunofluorescent staining, confocal imaging, immunoelectron microscopy, Western blot analysis, histologic analysis, and electroretinogram. RESULTS: The AAV-mediated whirlin expression started at two weeks, reached its maximum level at 10 weeks, and lasted up to six months post injection. The transgenic whirlin product had a molecular size and an expression level comparable to the wild-type. It was distributed at the PMC in both rod and cone photoreceptors from the central to peripheral retina. Importantly, the transgenic whirlin restored the cellular localization and expression level of both USH2A and VLGR1 and did not cause defects in the retinal histology and function in the whirlin knockout mouse. CONCLUSIONS:Whirlin transgene recruits USH2A and VLGR1 to the PMC and is sufficient for the formation of the USH2 protein complex in photoreceptors. The combined hRK and AAV gene delivery system could be an effective gene therapy approach to treat retinal degeneration in USH2D patients. Copyright 2011 The Association for Research in Vision and Ophthalmology, Inc.
Authors: Jun Yang; Xiaoqing Liu; Yun Zhao; Michael Adamian; Basil Pawlyk; Xun Sun; D Randy McMillan; M Charles Liberman; Tiansen Li Journal: PLoS Genet Date: 2010-05-20 Impact factor: 5.917
Authors: Grace S Yang; Michael Schmidt; Ziying Yan; Jonathan D Lindbloom; Thomas C Harding; Brian A Donahue; John F Engelhardt; Robert Kotin; Beverly L Davidson Journal: J Virol Date: 2002-08 Impact factor: 5.103
Authors: Avital Adato; Sarah Vreugde; Tarja Joensuu; Nili Avidan; Riikka Hamalainen; Olga Belenkiy; Tsviya Olender; Batsheva Bonne-Tamir; Edna Ben-Asher; Carmen Espinos; José M Millán; Anna-Elina Lehesjoki; John G Flannery; Karen B Avraham; Shmuel Pietrokovski; Eeva-Marja Sankila; Jacques S Beckmann; Doron Lancet Journal: Eur J Hum Genet Date: 2002-06 Impact factor: 4.246
Authors: Xiaoqing Liu; Oleg V Bulgakov; Xiao-Hong Wen; Michael L Woodruff; Basil Pawlyk; Jun Yang; Gordon L Fain; Michael A Sandberg; Clint L Makino; Tiansen Li Journal: Proc Natl Acad Sci U S A Date: 2004-09-13 Impact factor: 11.205
Authors: A Auricchio; G Kobinger; V Anand; M Hildinger; E O'Connor; A M Maguire; J M Wilson; J Bennett Journal: Hum Mol Genet Date: 2001-12-15 Impact factor: 6.150